Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study.

In our series, interestingly, low IGF-I performed better than PS in predicting worst patient outcome, being significant in univariate ( p = 0.037) and at the limits of significance in multivariate ( p = 0.054; see Table 5 ).

also in 23 other papers